InsidersTradesSigma
Track the Damora Therapeutics, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was filed on 6 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Firmani Lori. All data is accessible without an account.
Analysts rate Damora Therapeutics, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$44.67.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Damora Therapeutics, Inc. is a company focused on developing innovative therapies for disease treatment. It is listed on the XNAS market.